Literature DB >> 23714171

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

Edwin M Spithoven1, Esther Meijer, Wendy E Boertien, Steef J Sinkeler, Hilde Tent, Paul E de Jong, Gerjan Navis, Ron T Gansevoort.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by renal tubular cell proliferation and dedifferentiation, which may influence tubular secretion of creatinine (CCr[TS]). STUDY
DESIGN: Diagnostic test study. SETTING & PARTICIPANTS: We therefore investigated CCr(TS) in patients with ADPKD and controls and studied consequences for the performance of glomerular filtration rate (GFR) estimating equations. INDEX & REFERENCE TESTS: In patients with ADPKD and healthy controls, we measured GFR as (125)I-iothalamate clearance while simultaneously determining creatinine clearance. OTHER MEASUREMENTS: 24-hour urinary albumin excretion.
RESULTS: In 121 patients with ADPKD (56% men; mean age, 40 ± 11 [SD] years) and 215 controls (48% men; mean age, 53 ± 10 years), measured GFR (mGFR) was 78 ± 30 and 98 ± 17 mL/min/1.73 m(2), respectively, and CCr(TS) was 15.9 ± 10.8 and 10.9 ± 10.6 mL/min/1.73 m(2), respectively (P < 0.001). The higher CCr(TS) in patients with ADPKD remained significant after adjustment for covariates and appeared to be dependent on mGFR. Correlation and accuracy between mGFR and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) estimated GFR (eGFR) were 0.95 and 99%, respectively; between mGFR and MDRD (Modification of Diet in Renal Disease) Study eGFR, they were 0.93 and 97%, respectively. Values for bias, precision, and accuracy were similar or slightly better than in controls. In addition, change in mGFR during 3 years of follow-up in 45 patients with ADPKD correlated well with change in eGFR. LIMITATIONS: Cross-sectional, single center.
CONCLUSIONS: CCr(TS) in patients with ADPKD is higher than that in controls, but this effect is limited and observed at only high-normal mGFR. Consequently, the CKD-EPI and MDRD Study equations perform relatively well in estimating GFR and change in GFR in patients with ADPKD.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease (ADPKD); creatinine; estimated glomerular filtration rate (eGFR); measured GFR; tubular secretion of creatinine

Mesh:

Substances:

Year:  2013        PMID: 23714171     DOI: 10.1053/j.ajkd.2013.03.030

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

2.  Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan.

Authors:  Tsuyoshi Yamaguchi; Eiji Higashihara; Takatsugu Okegawa; Isao Miyazaki; Kikuo Nutahara
Journal:  Clin Exp Nephrol       Date:  2018-05-22       Impact factor: 2.801

3.  Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Chengli Shen; Douglas Landsittel; María V Irazabal; Alan S L Yu; Arlene B Chapman; Michal Mrug; Jared J Grantham; Kyongtae T Bae; William M Bennett; Michael F Flessner; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2016-12-24       Impact factor: 8.860

4.  Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.

Authors:  Rosa Miquel Rodríguez; Sergio Luis-Lima; Juan Manuel Fernandez; María Vanesa Pérez Gómez; Beatriz González Toledo; Marian Cobo; Patricia Delgado-Mallén; Beatriz Escamilla; Cristina Oramas Marco; Sara Estupiñán; Coriolano Cruz Perera; Natalia Negrín Mena; Laura Díaz Martín; Sergio Pitti Reyes; Ibrahim Hernández González; Federico González-Rinne; Alejandra González-Delgado; Carmen Ferrer-Moure; Begoña López-Botet Zulueta; Armando Torres; Jose Carlos Rodriguez Pérez; Flavio Gaspari; Alberto Ortiz; Esteban Porrini
Journal:  J Nephrol       Date:  2022-03-31       Impact factor: 4.393

5.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

6.  Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  A Lianne Messchendorp; Marco van Londen; Jacob M Taylor; Martin H de Borst; Gerjan Navis; Niek F Casteleijn; Carlo A J M Gaillard; Stephan J L Bakker; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-25       Impact factor: 8.237

Review 7.  A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.

Authors:  Claire Woon; Ashleigh Bielinski-Bradbury; Karl O'Reilly; Paul Robinson
Journal:  BMC Nephrol       Date:  2015-08-15       Impact factor: 2.388

Review 8.  Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Authors:  Ron T Gansevoort; Mustafa Arici; Thomas Benzing; Henrik Birn; Giovambattista Capasso; Adrian Covic; Olivier Devuyst; Christiane Drechsler; Kai-Uwe Eckardt; Francesco Emma; Bertrand Knebelmann; Yannick Le Meur; Ziad A Massy; Albert C M Ong; Alberto Ortiz; Franz Schaefer; Roser Torra; Raymond Vanholder; Andrzej Więcek; Carmine Zoccali; Wim Van Biesen
Journal:  Nephrol Dial Transplant       Date:  2016-01-29       Impact factor: 5.992

9.  Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.

Authors:  Laia Sans; Aleksandar Radosevic; Claudia Quintian; Rosario Montañés; Silvia Gràcia; Carles Vilaplana; Sergi Mojal; José A Ballarin; Patricia Fernández-Llama; Roser Torra; Julio Pascual
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

10.  The failure of glomerular filtration rate estimating equations among obese population.

Authors:  Piyawan Kittiskulnam; Krittaya Tiskajornsiri; Pisut Katavetin; Tawatchai Chaiwatanarat; Somchai Eiam-Ong; Kearkiat Praditpornsilpa
Journal:  PLoS One       Date:  2020-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.